-
公开(公告)号：US20180369280A1
公开(公告)日：2018-12-27
申请号：US16064161
申请日：2016-12-23
发明人： Thomas M. SCHMITT , Philip D. GREENBERG , Aude G. CHAPUIS , Harlan S. ROBINS , Anna M. SHERWOOD
摘要： The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human Wilms tumor protein 1 (WT 1) epitopes and mesothelin epitopes), T cells expressing such high affinity antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.
-
公开(公告)号：US20210379150A1
公开(公告)日：2021-12-09
申请号：US17408340
申请日：2021-08-20
发明人： Rachel PERRET , Philip D. GREENBERG , Thomas M. SCHMITT , Aude G. CHAPUIS , Ingunn M. STROMNES , Tijana MARTINOV
摘要： The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
-
公开(公告)号：US20220009992A1
公开(公告)日：2022-01-13
申请号：US17291985
申请日：2019-11-08
IPC分类号： C07K14/725 , C12N15/86 , A61K35/17 , A61K45/06 , A61P35/00
摘要： Binding proteins specific for Msln20-28 or Msln530-538 peptides are provided herein. Polynucleotides encoding the binding proteins, as well as compositions and recombinant host cells comprising the binding proteins or polynucleotides are also provided. The compositions and recombinant host cells may be used to treat a subject having mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, a cancer wherein an Msln20-28 peptide is expressed on a tumor cell of the cancer, or a cancer wherein an Msln530-538 peptide is expressed on a tumor cell of the cancer.
-
公开(公告)号：US20220160832A1
公开(公告)日：2022-05-26
申请号：US17643410
申请日：2021-12-08
发明人： Rachel PERRET , Philip D. GREENBERG , Thomas M. SCHMITT , Aude G. CHAPUIS , Ingunn M. STROMNES , Tijana MARTINOV
摘要： The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
-
公开(公告)号：US20220160764A1
公开(公告)日：2022-05-26
申请号：US17438380
申请日：2020-03-10
IPC分类号： A61K35/17 , C07K14/725 , C12N5/0783 , A61P35/00
摘要： The present disclosure provides T cell receptors (TCRs) and related binding proteins with high functional avidity against tumor associated antigen p37 from Wilms tumor protein 1 (WT1), T cells expressing such high affinity WT1 specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress WT1 and/or produce the p37 antigen, such as in cancer.
-
公开(公告)号：US20170362298A1
公开(公告)日：2017-12-21
申请号：US15692846
申请日：2017-08-31
IPC分类号： C07K14/725 , A61K38/17 , G01N33/569 , C12N5/0783 , A61K35/17 , C12N5/078 , A61K39/00
CPC分类号： C07K14/7051 , A61K35/17 , A61K38/1774 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , C12N5/0636 , C12N5/065 , C12N2501/42 , C12N2502/1394 , C12N2502/99 , G01N33/56966 , G01N2333/7051
摘要： The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCRα cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.
-
公开(公告)号：US20190127435A1
公开(公告)日：2019-05-02
申请号：US16094420
申请日：2017-04-20
IPC分类号： C07K14/725 , C07K14/715 , C07K14/705 , A61K35/17 , C12N5/0783
摘要： The present disclosure relates to fusion proteins containing an extracellular cytokine binding domain and an intracellular signaling domain of one or more IL-2R chains or signaling portion(s) thereof, wherein the cytokine binding domain is not an IL-2 binding domain. The present disclosure also relates to uses of immune cells expressing such fusion proteins to treat certain diseases, such as cancer or infectious disease.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
